Related Experiment Video
Updated: Jul 2, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and
Sungjoon Park1, Doyeon Hwang1, Jeehoon Kang1
1Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea.
Current Therapeutic Research, Clinical and Experimental
|February 21, 2024
Summary
A fixed-dose combination of telmisartan, amlodipine, and rosuvastatin (TEL/ALD/RSV) effectively lowered blood pressure and LDL-C in patients with hypertension and dyslipidemia compared to amlodipine/atorvastatin. No significant safety concerns were observed.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Hypertension and dyslipidemia are major risk factors for cardiovascular disease.
- Co-existing hypertension and dyslipidemia complicate treatment and affect patient adherence.
- Managing multiple medications for these conditions presents significant challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of a fixed-dose combination therapy for hypertension and dyslipidemia.
- To compare the effectiveness of telmisartan/amlodipine/rosuvastatin (TEL/ALD/RSV) against amlodipine/atorvastatin (ALD/ATV).
Main Methods:
- An 8-week, randomized, double-blind, multicenter, Phase IV clinical trial.
- Patients with essential hypertension and dyslipidemia were randomized into two groups.
- One group received TEL/ALD/RSV, while the other received ALD/ATV.
Main Results:
- The TEL/ALD/RSV group showed a significantly greater reduction in systolic blood pressure (-16.27 mm Hg) compared to the ALD/ATV group (-6.85 mm Hg).
- TEL/ALD/RSV also achieved a more significant reduction in LDL-C levels (-50.03%) versus ALD/ATV (-39.60%).
- No severe adverse events were reported in either treatment group.
Conclusions:
- Fixed-dose combination TEL/ALD/RSV demonstrated superior efficacy in managing both blood pressure and LDL-C levels.
- The TEL/ALD/RSV combination offers a safe and effective treatment option for patients with co-existing hypertension and dyslipidemia.
- This study supports the use of TEL/ALD/RSV as a valuable therapeutic strategy in cardiovascular disease management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
448
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731